EDElizabeth Van Dril

Elizabeth Van Dril

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elizabeth Van Dril has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Describing pharmacists' perspectives on current practices and barriers to outpatient glucagon use in people with diabetes

    by Carrie Yu, Christine Schumacher, Ana C. Quiñones-Boex, Elizabeth Van Dril

  • Factors That Influence Blood Pressure Changes With the Use of Sodium‐Glucose Cotransporter 2 Inhibitors in People With Type 2 Diabetes

    by Sara Salama, Charlotte Bolch, Dejan Landup, Elizabeth Van Dril, Christie Schumacher

    Study Objective: Multiple clinical trials have reported variable reductions in blood pressure with sodium–glucose cotransporter 2 (SGLT2) inhibitors. Given the variability in the magnitude of blood pressure reduction observed across studies, there is interest in understanding how patient‐specific factors influence the blood pressure‐lowering effects of SGLT2 inhibitors. The primary objective of this study was to evaluate factors that influence blood pressure changes in people with type 2 diabetes when an SGLT2 inhibitor is initiated. Design: Multicenter retrospective cohort chart review. Data Source: Patients were selected through an electronic medical record‐generated report between January 1, 2013, and September 30, 2019. Patients: Adults (≥ 18 years) receiving care within Advocate Medical Group were included if they had a documented diagnosis of type 2 diabetes and had been prescribed one of four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin) for at least 7 days. Results: In 1,422 patients, mean systolic blood pressure (SBP) decreased by 4.1 mmHg (range −58.7 to 58.0), and mean diastolic blood pressure (DBP) decreased by 2.1 mmHg (range −44.7 to 29.0) after SGLT2 inhibitor initiation. Significant blood pressure reductions occurred only in patients with elevated baseline blood pressure, with greater declines at higher baseline pressures ( p < 0.001). Patients with baseline SBP > 160 mmHg showed a mean reduction of 26.7 mmHg, whereas those with SBP < 120 mmHg had a mean increase of 6.1 mmHg. DBP followed a similar pattern: Individuals with baseline DBP > 100 mmHg had a mean reduction of 16.0 mmHg, whereas those with DBP < 60 mmHg experienced a mean increase of 10.7 mmHg. Conclusion: Blood pressure responses to SGLT2 inhibitors were driven by baseline blood pressure, with the greatest reductions observed in patients with elevated blood pressure at initiation. Individuals with lower starting pressures showed minimal change or slight increases, indicating a normalizing effect rather than uniform blood pressure lowering with initiation of SGLT2 inhibitors. These findings support incorporating baseline blood pressure into treatment selection to optimize cardiovascular risk management in patients with type 2 diabetes.

  • The Cost Conundrum: Pharmacists at the Crossroads of Evidence and Affordability

    by Dejan Landup, Emily Hanners Dunn, Elizabeth Van Dril, Robert J. DiDomenico

  • Open Access

    The Pharmacist's Role in the Use of Incretin‐Based Therapies for Weight Management: An Opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy

    by Sara Lingow, Nicholas Carris, Jennifer Clements, Lindsay Courtney, Abby Lennon, Christina H. Sherrill, Elizabeth Van Dril

    The popularity of incretin‐based therapies has increased substantially over the past several years due to their clinically significant efficacy for weight loss and positive impact on weight‐related comorbid conditions, yet, few clinical practice guidelines for the management of overweight and obesity have been updated to incorporate these agents. The increased demand for incretin‐based therapies for weight management has revealed barriers to their implementation related to cost, availability, and emerging safety concerns. This opinion paper aims to briefly review the available literature on the current role of incretin‐based therapy for chronic weight management in persons with overweight or obesity and provide recommendations for clinical pharmacists utilizing these agents. The intent of this opinion paper is to discuss the benefits and risks of incretin‐based therapy for weight management, review approaches for clinical pharmacists to overcome barriers to their implementation, and address ongoing questions related to their use. Finally, the authors suggest an approach to the management of people with overweight or obesity with incretin‐based therapy using the Pharmacists' Patient Care Process along with actions clinical pharmacists can take to ensure best practices with these agents.


  • Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors

    by Kellye Eagan, Charlotte Bolch, Elizabeth Van Dril, Christie Schumacher

    Study Objective: The primary objective of this study was to determine if there was a significant change in potassium levels with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor therapy in people with type 2 diabetes (T2D). A co‐primary objective was to evaluate which factors may predispose a patient to changes in potassium levels. Design: Multicenter retrospective cohort chart review. Data Source: Study patients were identified through an electronic medical record‐generated report if they had T2D and were prescribed an SGLT2 inhibitor from January 2013 to September 2019. Patients: Patients were included if they had T2D, were receiving care at Advocate Medical Group, and were confirmed to have taken one of the four SGLT2 inhibitors available at the time of study approval, canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin, for at least 7 days. Patients were excluded if they did not have a basic metabolic panel or comprehensive metabolic panel recorded 1 year prior to or 6 months after SGLT2 inhibitor therapy initiation. Results: Data extraction from the electronic medical record identified 6425 patients receiving an SGLT2 inhibitor, of which 1926 met inclusion criteria. The SGLT2 inhibitor most prescribed was canagliflozin (43.7%), followed by empagliflozin (36.9%) and dapagliflozin (19.4%). Concomitant baseline medications were thiazide diuretics (27.5%); angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor‐neprilysin inhibitors (72.1%); and/or mineralocorticoid receptor antagonists (27.2%). A statistically significant change in potassium levels was found with dapagliflozin ( p = 0.018); albeit not clinically significant. No other statistically significant changes or patterns were identified. The overall mean change in serum potassium from baseline was 0.021 mmol/L within 3 months; 0.007 mmol/L from 3 to 5.9 months; −0.017 mmol/L within 6–12 months; and 0.004 mmol/L after more than 12 months. Conclusions: No clinically significant increase or decrease in potassium levels was observed upon initiation of SGLT2 inhibitor therapy in patients with T2D. This was consistent across background medication use and patient‐specific factors. Baseline potassium should not be a factor in initiating SGLT2 inhibitor therapy, if clinically indicated, in patients with T2D.


  • Identifying ideal pharmacist‐to‐patient ratios for the successful provision of clinical pharmacy services

    by Jay L. Martello, Zack Dumont, Wiyanna Bruck, Mitchell S. Buckley, Christopher T. Buckley, Nicolette Centanni, Elizabeth A. Chester, Jeffrey Gonzales, Gina Harper, Miranda Howland, et al.

    Clinical pharmacists add significant value to the health care team and are associated with reduced hospital mortality, drug costs, length of stay, and adverse drug reactions. However, there remains a paucity of evaluative data regarding optimal clinical pharmacy practice models. Identifying optimal patient (or bed)‐to–clinical pharmacist ratios is one mechanism to assess the allocation of resources. The ACCP Task Force on Clinical Pharmacy Services was charged with developing a white paper to examine optimal ratios in different care settings, considering confounders and other factors that affect the interpretation of ratio data. The committee performed an extensive search of the pharmacy, medical, and nursing literature to identify existing data on provider‐to‐patient ratios. Recommendations on ratios are mainly from survey data or statements from various health care organizations. Many factors affect the capacity of clinical pharmacists to achieve patient care and non‐patient care responsibilities. Examples include general differences in baseline expectations; nonstandardized program performance metrics; variable hospital/practice setting types; variable patient acuity and complexity; competing priorities and other resources; industry‐wide rates of and variability in addressing burnout; inconsistent means for justifying numbers and historical corporate structures; and external endorsements and mandates. Although some areas of practice such as critical care pharmacy have more robust evidence for specific ratios, others such as pediatrics are far less clear. A clinical pharmacist ratio must be established as a starting point. This will allow for better allocation today and serve as a springboard for future determinations. Furthermore, clinical pharmacist ratios should be preserved to offer reliable patient care 365 days per year. As clinical pharmacist services shift from beneficial to essential, continuous daily patient care services must be the practice model moving forward.


  • Identification of risk factors associated with acute kidney injury in patients taking sodium‐glucose cotransporter‐2 inhibitors

    by Christie Schumacher, Amanda Chorpash, Charlotte Bolch, Kellye Eagan, Sara Nimer, Elizabeth Van Dril

    Study Objective: Studies have demonstrated sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are kidney protective; however, their ability to cause hemodynamic changes may predispose patients to acute kidney injury (AKI). An FDA warning recommends evaluating for factors that predispose patients to AKI before initiating a SGLT2 inhibitor. The primary objective of this study is to identify risk factors that may predispose persons with diabetes to AKI when initiating SGLT2 inhibitor therapy.Design: Multicenter retrospective cohort chart review.Data Source: Study patients were identified through an electronic medical record generated report if they had type 2 diabetes and were prescribed a SGLT2 inhibitor from January 2013 to September 2019.Patients: Patients were included if they were receiving care at Advocate Medical Group and were confirmed to have taken one of the four SGLT2 inhibitors available at the time of study approval, canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin, for at least 7 days. Patients were excluded if they did not have a basic metabolic panel or comprehensive metabolic panel recorded 1 year prior to or 6 months after SGLT2 inhibitor therapy initiation.Results: Data extraction from the electronic medical record identified 6425 patients receiving a SGLT2 inhibitor, of which 1962 met inclusion criteria and were included for analysis. Thirty‐five (1.8%) patients experienced an AKI after SGLT2 inhibitor therapy initiation. There was no statistically significant difference between groups based on background medication use (p = 0.325). At baseline, patients experiencing an AKI after SGLT2 inhibitor initiation were more likely to be older in age (p = 0.010), have a higher serum potassium (p < 0.001), blood glucose (p = 0.018), SCr (p = 0.009) and UACR (p < 0.001), and a lower eGFR (p = 0.028) compared to those who did not experience AKI.Conclusions: The transient eGFR decline with SGLT2 inhibitor initiation should be expected and is generally not an indication to discontinue therapy. Future initiatives should be directed at increasing knowledge of monitoring recommendations for these agents.


  • Open Access

    Evaluation of the accuracy of a mandatory indication field for outpatient antibiotic prescriptions

    by Johanna Papanikolla, Adam Bursua, Jonathan Radosta, Scott A. Borgetti, Susan Bleasdale, Elizabeth Van Dril, John Shilka, Alan E. Gross